Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2019

24.10.2018 | Gynecologic Oncology

A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients

verfasst von: Anne-Sophie Heimes, Marcus Schmidt, Joerg Jäkel, Katrin Almstedt, Susanne Gebhard, Veronika Weyer-Eiberich, Tania Elger, Slavomir Krajnak, Walburgis Brenner, Annette Hasenburg, Marco Johannes Battista

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Tumor-infiltrating lymphocytes influence the prognosis of solid tumors, including ovarian cancer (OC). The immunoregulatory transcription factor (IRF4) is mainly expressed in plasma cells and regulates immunoglobulin class switch recombination as well as plasma cell differentiation. Therefore, we analyzed the impact of IRF4 expression in a consecutive cohort of OC patients.

Methods

IRF4 expression was evaluated by immunostaining. Differences in IRF4 expression among the subgroups of the established clinical−pathological features like age, histological subtype, tumor stage, histological grading, postoperative tumor burden, and completeness of chemotherapy were determined by χ2 test. The impact of IRF4 expression on progression-free survival (PFS) and overall survival (OS) was examined by univariate and multivariate Cox analysis adjusted for established clinical−pathological factors and Kaplan–Meier survival analysis.

Results

114 patients entered this study. IRF4 was expressed in 51.7% of the entire cohort. 72.3% patients with high-grade serous OC showed IRF4 expression compared to 37.3% patients with a non-high-grade serous OC (p < 0.001). Univariate Cox-regression analysis revealed no prognostic impact of IRF4 expression in terms of PFS (p = 0.35) and OS (p = 0.98). Kaplan–Meier plots failed to show any prognostic impact for PFS (p = 0.35) and OS (p = 0.98), too. Established clinical–pathological factors retained their prognostic impact as tumor stage in terms of PFS (< 0.001) and as postoperative residual tumor burden (p = 0.04), tumor stage (< 0.001), histological grade (p = 0.02), and completeness of chemotherapy (p < 0.001) in terms of OS, respectively.

Conclusion

Immunohistochemically determined IRF4 expression correlated with high-grade serous OC. However, it failed to show any prognostic impact in this cohort of 114 patients.
Literatur
2.
3.
Zurück zum Zitat Milne K et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4(7):e6412CrossRefPubMedPubMedCentral Milne K et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4(7):e6412CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Stumpf M et al (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101(9):1513–1521CrossRefPubMedPubMedCentral Stumpf M et al (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101(9):1513–1521CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Santoiemma P et al (2016) Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120–127CrossRefPubMed Santoiemma P et al (2016) Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120–127CrossRefPubMed
6.
7.
Zurück zum Zitat Kurman RJ et al (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 24(Suppl 10):16–21CrossRef Kurman RJ et al (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 24(Suppl 10):16–21CrossRef
8.
10.
Zurück zum Zitat Schmidt M et al (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695–2703CrossRefPubMed Schmidt M et al (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695–2703CrossRefPubMed
13.
Zurück zum Zitat Chang CC et al (2002) IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002(100):4671–4675CrossRef Chang CC et al (2002) IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002(100):4671–4675CrossRef
14.
Zurück zum Zitat Battista MJ et al (2016) c-met is overexpressed in type I ovarian cancer: results of an investigative analysis in a cohort of consecutive ovarian cancer patients. Oncol Lett 12(3):2001–2007CrossRefPubMedPubMedCentral Battista MJ et al (2016) c-met is overexpressed in type I ovarian cancer: results of an investigative analysis in a cohort of consecutive ovarian cancer patients. Oncol Lett 12(3):2001–2007CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kurman RJ et al (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol 42(7):918–931CrossRefPubMedPubMedCentral Kurman RJ et al (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol 42(7):918–931CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Salgado R et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271CrossRefPubMed Salgado R et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271CrossRefPubMed
18.
Zurück zum Zitat Landen CN et al (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995–1005CrossRefPubMed Landen CN et al (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995–1005CrossRefPubMed
19.
Zurück zum Zitat Al Chapoval et al (1998) Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161(12):6977–6984 Al Chapoval et al (1998) Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161(12):6977–6984
20.
Zurück zum Zitat Nielsen JS et al (2012) CD20 + tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8 + T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281–3292CrossRefPubMed Nielsen JS et al (2012) CD20 + tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8 + T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281–3292CrossRefPubMed
22.
Zurück zum Zitat Kroeger DR et al (2016) Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 22(12):3005–3015CrossRefPubMed Kroeger DR et al (2016) Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 22(12):3005–3015CrossRefPubMed
23.
Zurück zum Zitat Iglesia MD et al (2014) Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20(14):3818–3829CrossRefPubMedPubMedCentral Iglesia MD et al (2014) Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20(14):3818–3829CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Montfort A et al (2017) A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res 23(1):250–262CrossRefPubMed Montfort A et al (2017) A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res 23(1):250–262CrossRefPubMed
Metadaten
Titel
A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients
verfasst von
Anne-Sophie Heimes
Marcus Schmidt
Joerg Jäkel
Katrin Almstedt
Susanne Gebhard
Veronika Weyer-Eiberich
Tania Elger
Slavomir Krajnak
Walburgis Brenner
Annette Hasenburg
Marco Johannes Battista
Publikationsdatum
24.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-018-4941-z

Weitere Artikel der Ausgabe 1/2019

Archives of Gynecology and Obstetrics 1/2019 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.